Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

The equity awards carry service-based vesting, with different installment schedules for options and restricted stock units.

Rhea-AI Summary

Atrium Therapeutics (RNA) awarded stock options and restricted stock units to one newly hired non-executive employee as an employment inducement. The grants comprise options to purchase 9,500 shares at $7.98 per share, the closing share price on the grant's effective date, and restricted stock units covering 4,750 shares.

Both awards vest 25% on the first grant anniversary. The remaining options vest in 36 substantially equal monthly installments; the remaining restricted stock units vest in three substantially equal annual installments. Vesting requires continued service through each applicable date. The independent Human Capital Management Committee approved the awards under the 2026 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.9,500 stock options at $7.98 per share create potential dilution as they vest and are exercised.
• Minor point. Forward-looking: it has not happened yet and may not happen.4,750 restricted stock units create potential dilution, subject to continued-service vesting.

Key Figures

Stock options: 9,500 shares Option exercise price: $7.98 per share Option vesting: 25% after 1 year; remaining shares in 36 monthly installments +2 more

Stock options

9,500 shares

Inducement award to one newly hired employee

Option exercise price

$7.98 per share

Closing price on the grant's effective date

Option vesting

25% after 1 year; remaining shares in 36 monthly installments

Subject to continued service

Restricted stock units

4,750 shares

Inducement award to one newly hired employee

Restricted stock unit vesting

25% after 1 year; remaining shares in 3 annual installments

Subject to continued service

Historical Context

2 past events · Latest: Sep 21

2 events

1. Sep 21

   Inducement grants

   24h Move

   +0.3%

   One new hire received options for 13,500 shares and 6,750 restricted stock units under the same plan.

2. Aug 20

   Inducement grants

   24h Move

   -2.1%

   One new hire received options for 11,000 shares and 5,500 restricted stock units under the same plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"non-qualified stock options to purchase 9,500 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"restricted stock units for an aggregate of 4,750 shares"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on October 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of one non-executive individual newly hired by the Company.

The employee received, in the aggregate, non-qualified stock options to purchase 9,500 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $7.98 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 4,750 shares of the Company's common stock, 25% of which will vest on the first anniversary of the grant date, and the remaining underlying shares will vest in 3 substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."

All of the above-described Awards were granted pursuant to the 2026 Inducement Plan. The Awards were approved by the Human Capital Management Committee of the Company's Board of Directors, which is comprised solely of independent directors, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. With the U.S. Food and Drug Administration's (FDA) clearance of its Investigational New Drug (IND) application for ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome, Atrium is advancing its first precision cardiology program into the clinic through the Corventis Phase 1/2 clinical trial. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies. For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302914657.html

SOURCE Atrium Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Atrium Therapeutics grant its new employee?

Atrium Therapeutics granted one newly hired non-executive employee 9,500 stock options with a $7.98 exercise price and restricted stock units covering 4,750 shares. The awards were granted on October 20, 2026, as an employment inducement.

How do Atrium Therapeutics' employee inducement awards vest?

Both awards vest 25% on the first anniversary of the grant date, subject to continued service. The remaining options vest in 36 substantially equal monthly installments, while the remaining restricted stock units vest in three substantially equal annual installments. Continued service is required through each applicable vesting date.